Is MANNKIND CORP (MNKD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.9% / 30% | 24.5% / 30% | 1.5% / 30% | 4.42% / 5% | ✓ HALAL |
| DJIM | 5.9% / 33% | 24.5% / 33% | 1.5% / 33% | 4.42% / 5% | ✓ HALAL |
| MSCI | 12.1% / 33% | 50.1% / 33% | 3.0% / 33% | 4.42% / 5% | ✗ NOT HALAL |
| S&P | 5.9% / 33% | 24.5% / 33% | 1.5% / 33% | 4.42% / 5% | ✓ HALAL |
| FTSE | 12.1% / 33% | 50.1% / 33% | 3.0% / 50% | 4.42% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 74.8% | |
| Operating Margin | -6.9% | |
| Net Margin | 1.7% | |
| Return on Assets (ROA) | 4.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $18M |
| Free Cash Flow | $14M |
| Total Debt | $367M |
| Current Ratio | 1.7 |
| Total Assets | $792M |
Price & Trading
| Last Close | $2.30 |
| 50-Day MA | $4.31 |
| 200-Day MA | $4.75 |
| Avg Volume | 5.4M |
| Beta | 0.9 |
|
52-Week Range
$2.23
| |
About MANNKIND CORP (MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Purification Calculator
As a halal stock with 4.42% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MANNKIND CORP (MNKD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MANNKIND CORP is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MANNKIND CORP's debt ratio?
MANNKIND CORP's debt ratio is 5.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.1%.
Does MANNKIND CORP require dividend purification?
Yes, MANNKIND CORP has an impermissible income ratio of 4.42%, which means 4.42% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are MANNKIND CORP's key financial metrics?
MANNKIND CORP has a market capitalization of $702M, trailing P/E ratio of 114.0, and revenue of $349M. The company maintains a gross margin of 74.8% and a net margin of 1.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.